Quality of life · adults and children with hemophilia A or B with inhibitors
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Safety of bypassing agents · adults and children with hemophilia A or B with inhibitors
1 finding from 1 review
Number of total bleeds per year or bleeding frequency · adults and children with hemophilia A or B with inhibitors
1 finding from 1 review
Annualised bleeding rate · adults and children with hemophilia A or B with inhibitors
1 finding from 1 review
Target joint bleeding rate · adults and children with hemophilia A or B with inhibitors
1 finding from 1 review
Short‐term (1 week) percentage change (improvement) in overall speech production · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Short‐term (within 1 month) change in isolated movement, objective and subjective measures of speech production Cooper 2008 reported 3 speech measures: ICARS speech subscale. Scale from: 0 to 8. Higher scores indicate greater clinical severity Syl... · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Short‐term (within 1 month) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Adverse effects (during study) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Economic outcomes · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Thrombosis · people with antiphospholipid antibodies and no history of thrombosis
1 finding from 1 review
Bleeding ‐ major/excessive · people with antiphospholipid antibodies and no history of thrombosis
1 finding from 1 review
Subcutaneous bruises · people with antiphospholipid antibodies and no history of thrombosis
ASA + high‐dose LMWH showed no clear difference in subcutaneous bruises compared with ASA + low‐dose LMWH or UFH (low certainty).
1 finding from 1 review
All‐cause mortality · people with antiphospholipid antibodies and no history of thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with antiphospholipid antibodies and no history of thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events other than bleeding · people with antiphospholipid antibodies and no history of thrombosis
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
Adverse events · children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospital admissions · children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found